Share This

Related Topics News -

     
 Title only   |   Print    Next page > 
     
騰盛博藥治療乙肝藥物獲內地納入突破性治療品種

2024-05-14T  
《公司業績》騰盛博藥全年虧損收窄至1.75億人民幣

2024-03-24T  
騰盛博藥及開拓藥業跌逾8% 惟來凱醫藥回升12%

2024-02-28T  
藥明系受捧 升逾4%-7%

2024-02-26T  
《大行報告》中金:國指及科指檢討結果料對聯通及同程影響正面 22隻股份或符納入港股通

2024-02-20T  
騰盛博藥-B收購HBV藥物知識產權及癌症疫苗亞太區開發權

2024-02-14T  
藥明系急瀉殃及同業 百濟神州及金斯瑞挫8%至9% 復星醫藥創逾十年低

2024-02-02T  
醫藥股普遍捱沽 榮昌生物挫一成

2024-01-19T  
醫藥板塊上揚 威高股份、中國中藥、綠葉、康方及宜明昂科升6%-11%

2024-01-09T  
醫藥股普遍捱沽 信達、翰森及百濟神州跌6%-7%

2024-01-05T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.